Compare eBay Inc (EBAY) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
eBay Inc vs Sanofi SA — how do they compare? eBay Inc trades at $110.95 (market cap $50.07B), while Sanofi SA trades at $44.16 (market cap $103.94B). The key difference: Sanofi SA is far larger — about 2.1× eBay Inc's market cap, and Sanofi SA pays the higher dividend (5.54%). Which is the better fit depends on your goals.
| EBAY | SNY | |
|---|---|---|
Market Cap | $50.07B | $103.94B |
Volume | 5,186,418 | — |
Sector | Consumer Cyclical | Health |
52-Week High | $118.96 | $52.34 |
52-Week Low | $76.79 | $41.33 |
Enterprise Value | $53.41B | $120.43B |
Dividend Yield | 1.1% | 5.54% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EBAY trades at $111.48, down 0.94% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported revenue of $11.10B in 2025 with a net income margin of 17.61%, and has beaten EPS estimates for three consecutive quarters. Recent news highlights eBay's cleared acquisition of Depop and ongoing takeover interest from GameStop.
EBAY presents a mixed outlook with strong profitability and consistent earnings beats offset by high valuation multiples and competitive pressures. The stock's upside potential hinges on successful integration of acquisitions and advertising growth, while risks include market volatility and execution challenges in a dynamic e-commerce landscape.
Sanofi (SNY) trades at $44.11, up 2.15% today, with a bullish technical signal supported by moving averages. The company shows strong fundamentals with a P/E of 19.37, net income margin of 15.95%, and consistent earnings beats in recent quarters. Recent FDA approval for Sarclisa's subcutaneous formulation and EU clearance for Cenrifki highlight pipeline progress, while a dividend of $2.42 per share underscores shareholder returns.
Outlook remains positive driven by Dupixent growth and new drug approvals, though risks include EU antitrust probes and competitive pressures. Analysts are mixed with 44% buy ratings, suggesting cautious optimism. The stock presents value with solid cash flow and profitability, but investors should monitor regulatory developments and pipeline execution for sustained upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About eBay Inc
eBay Inc. is a global commerce company. The Company's platforms are designed to enable sellers worldwide to organize and offer their inventory for sale and buyers to find and buy it. eBay's items can be new or used, plain or luxurious, commonplace or rare, trendy or one-of-a-kind.
Read more on EBAY →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
